AMRI’s Burlington facility granted AIFA authorization to manufacture octreotide AMRI announced today that it has received authorization from the Italian Medicines Agency because of its facility in Burlington, MA to manufacture the commercial drug product octreotide for a person in europe . This certification specifically applies to laboratories and developing areas at the company’s Burlington facility designed for the production of aseptic and lyophilized vials, affirming the facility’s compliance with EU GMP criteria generic cialis 20mg .